Tune in to our upcoming broadcast to learn more about advances in the treatment of tenosynovial giant cell tumor. Register today!

NCCN Guidelines for Genetic Testing in Prostate Cancer

Thursday, March 28, 2019

Emmanuel S. Antonarakis, MBBCh, an associate professor of oncology at Johns Hopkins Medicine, discussed updated National Comprehensive Cancer Network (NCCN) guidelines for the genetic testing of men with prostate cancer.

Germline testing, which looks for inherited gene mutations, and somatic testing, which examines the genetic makeup of the tumor itself, can be useful in making therapy decisions. According to the NCCN, every patient with metastatic or high-risk localized non-metastatic prostate cancer should undergo germline testing. Additionally, men with lymph node metastases or distant metastases should undergo genetic testing.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.